Tenax Therapeutics (TENX) Competitors

Tenax Therapeutics logo
$1.42 -0.06 (-4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 +0.04 (+2.46%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TENX vs. SPRY, TTRX, CGC, BIOA, and AMRN

Should you buy Tenax Therapeutics stock or one of its competitors? Tenax Therapeutics's main competitors and comparable companies include ARS Pharmaceuticals (SPRY), Turn Therapeutics (TTRX), Canopy Growth (CGC), BioAge Labs (BIOA), and Amarin (AMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tenax Therapeutics compare to ARS Pharmaceuticals?

Tenax Therapeutics (NASDAQ:TENX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Tenax Therapeutics presently has a consensus price target of $14.00, indicating a potential upside of 845.95%. ARS Pharmaceuticals has a consensus price target of $23.33, indicating a potential upside of 549.95%. Given Tenax Therapeutics' higher probable upside, equities research analysts clearly believe Tenax Therapeutics is more favorable than ARS Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.40
ARS Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

In the previous week, Tenax Therapeutics had 20 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 22 mentions for Tenax Therapeutics and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.40 beat Tenax Therapeutics' score of 0.03 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tenax Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
ARS Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 10.8% of Tenax Therapeutics shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Tenax Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.39N/A
ARS Pharmaceuticals$84.28M4.28-$171.30M-$2.02N/A

Tenax Therapeutics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market.

Tenax Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -163.64%. Tenax Therapeutics' return on equity of -60.61% beat ARS Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -60.61% -56.44%
ARS Pharmaceuticals -163.64%-453.93%-71.62%

Summary

Tenax Therapeutics beats ARS Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Turn Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Turn Therapeutics currently has a consensus price target of $9.00, indicating a potential upside of 5.26%. Tenax Therapeutics has a consensus price target of $14.00, indicating a potential upside of 845.95%. Given Tenax Therapeutics' higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Turn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Turn Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
2 Strong Buy rating(s)
2.67
Tenax Therapeutics
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.40

Tenax Therapeutics' return on equity of -60.61% beat Turn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Turn TherapeuticsN/A -261.87% -70.18%
Tenax Therapeutics N/A -60.61%-56.44%

In the previous week, Tenax Therapeutics had 20 more articles in the media than Turn Therapeutics. MarketBeat recorded 22 mentions for Tenax Therapeutics and 2 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.48 beat Tenax Therapeutics' score of 0.03 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Turn Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tenax Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Turn Therapeutics is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Turn TherapeuticsN/AN/A-$3.19M-$0.43N/A
Tenax TherapeuticsN/AN/A-$52.60M-$1.39N/A

1.7% of Tenax Therapeutics shares are owned by institutional investors. 55.9% of Turn Therapeutics shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Turn Therapeutics and Tenax Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Tenax Therapeutics compare to Canopy Growth?

Tenax Therapeutics (NASDAQ:TENX) and Canopy Growth (NASDAQ:CGC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Tenax Therapeutics has higher earnings, but lower revenue than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.39N/A
Canopy Growth$251.01M0.92-$190.29M-$0.51N/A

Tenax Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Canopy Growth has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market.

1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 3.3% of Canopy Growth shares are owned by institutional investors. 10.8% of Tenax Therapeutics shares are owned by insiders. Comparatively, 0.4% of Canopy Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tenax Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -73.03%. Canopy Growth's return on equity of -28.21% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -60.61% -56.44%
Canopy Growth -73.03%-28.21%-17.97%

Tenax Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 845.95%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenax Therapeutics is more favorable than Canopy Growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.40
Canopy Growth
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, Tenax Therapeutics had 19 more articles in the media than Canopy Growth. MarketBeat recorded 22 mentions for Tenax Therapeutics and 3 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 1.31 beat Tenax Therapeutics' score of 0.03 indicating that Canopy Growth is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tenax Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Canopy Growth
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Tenax Therapeutics beats Canopy Growth on 10 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to BioAge Labs?

Tenax Therapeutics (NASDAQ:TENX) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Tenax Therapeutics has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, BioAge Labs has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market.

Tenax Therapeutics has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenax TherapeuticsN/AN/A-$52.60M-$1.39N/A
BioAge Labs$8.99M26.69-$80.61M-$2.55N/A

1.7% of Tenax Therapeutics shares are held by institutional investors. 10.8% of Tenax Therapeutics shares are held by insiders. Comparatively, 17.6% of BioAge Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tenax Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -1,253.60%. BioAge Labs' return on equity of -31.42% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tenax TherapeuticsN/A -60.61% -56.44%
BioAge Labs -1,253.60%-31.42%-29.59%

In the previous week, Tenax Therapeutics had 18 more articles in the media than BioAge Labs. MarketBeat recorded 22 mentions for Tenax Therapeutics and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.48 beat Tenax Therapeutics' score of 0.03 indicating that BioAge Labs is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tenax Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
BioAge Labs
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Tenax Therapeutics currently has a consensus target price of $14.00, suggesting a potential upside of 845.95%. BioAge Labs has a consensus target price of $33.00, suggesting a potential upside of 532.18%. Given Tenax Therapeutics' higher probable upside, research analysts clearly believe Tenax Therapeutics is more favorable than BioAge Labs.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tenax Therapeutics
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.40
BioAge Labs
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Summary

Tenax Therapeutics and BioAge Labs tied by winning 8 of the 16 factors compared between the two stocks.

How does Tenax Therapeutics compare to Amarin?

Amarin (NASDAQ:AMRN) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

Tenax Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -10.87%. Amarin's return on equity of -0.52% beat Tenax Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-10.87% -0.52% -0.36%
Tenax Therapeutics N/A -60.61%-56.44%

In the previous week, Tenax Therapeutics had 18 more articles in the media than Amarin. MarketBeat recorded 22 mentions for Tenax Therapeutics and 4 mentions for Amarin. Amarin's average media sentiment score of 0.38 beat Tenax Therapeutics' score of 0.03 indicating that Amarin is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amarin
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Tenax Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
20 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Amarin has higher revenue and earnings than Tenax Therapeutics. Amarin is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$213.65M1.12-$38.80M-$0.96N/A
Tenax TherapeuticsN/AN/A-$52.60M-$1.39N/A

22.3% of Amarin shares are owned by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are owned by institutional investors. 4.2% of Amarin shares are owned by insiders. Comparatively, 10.8% of Tenax Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Amarin has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Amarin presently has a consensus price target of $13.00, indicating a potential upside of 14.94%. Tenax Therapeutics has a consensus price target of $14.00, indicating a potential upside of 845.95%. Given Tenax Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33
Tenax Therapeutics
1 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.40

Summary

Tenax Therapeutics beats Amarin on 9 of the 16 factors compared between the two stocks.

Get Tenax Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TENX vs. The Competition

MetricTenax TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$67.39M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E Ratio-1.0229.4034.1729.86
Price / SalesN/A7.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book0.595.114.373.66
Net Income-$52.60M$2.88B$3.52B$392.27M
7 Day Performance-15.98%-4.10%-5.47%-4.73%
1 Month Performance4.41%-5.08%-4.57%-7.14%
1 Year Performance-80.68%-7.47%-1.79%-7.51%

Tenax Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TENX
Tenax Therapeutics
4.2381 of 5 stars
$1.42
-4.1%
$14.00
+885.9%
-79.2%$67.39MN/AN/A16
SPRY
ARS Pharmaceuticals
2.5863 of 5 stars
$3.57
+13.3%
$23.33
+553.6%
-56.3%$316.66M$84.28MN/A200
TTRX
Turn Therapeutics
1.5412 of 5 stars
$9.92
+1.3%
$9.00
-9.3%
+113.8%$298.92MN/AN/A2
CGC
Canopy Growth
1.1741 of 5 stars
$0.59
-4.9%
N/A-48.8%$279.82M$251.01MN/A1,128
BIOA
BioAge Labs
2.6847 of 5 stars
$5.78
+1.6%
$33.00
+470.9%
-33.1%$261.15M$8.60MN/A62

Related Companies and Tools


This page (NASDAQ:TENX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners